Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True?

被引：18
|
作者：
Kaul, Sanjay [1 ]
机构：
[1] Cedars Sinai Med Ctr, Div Cardiol, 8635 W Third St,Ste 790W, Los Angeles, CA 90048 USA
来源：
CIRCULATION | 2016年 / 134卷 / 02期
关键词：
clinical trial; diabetes mellitus; mortality; TRIAL;
D O I：
10.1161/CIRCULATIONAHA.116.022537
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：94 / +
页数：11
相关论文
共 50 条
  • [41] Pilot study in pharmacogenomic management of empagliflozin in type 2 diabetes mellitus patients
    Mahdieh Jamalizadeh
    Mandana Hasanzad
    Negar Sarhangi
    Farshad Sharifi
    Ensieh Nasli-Esfahani
    Bagher Larijani
    Journal of Diabetes & Metabolic Disorders, 2021, 20 : 1407 - 1413
  • [42] Sympathetic Activity in Patients with Type 2 Diabetes Mellitus Treated with Empagliflozin or Hydrochlorothiazide
    Heusser, Karsten
    Tank, Jens
    Fischer, Annelie
    Heise, Tim
    Jordan, Jens
    DIABETES, 2022, 71
  • [43] Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus
    Al Jobori, Hussein
    Daniele, Giuseppe
    Adams, John
    Cersosimo, Eugenio
    Solis-Herrera, Carolina
    Triplitt, Curtis
    DeFronzo, Ralph A.
    Abdul-Ghani, Muhammad
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2018, 103 (04): : 1402 - 1407
  • [44] Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes Mellitus
    Albugami, Muneerah M.
    Ahmed, Mohammed
    Alobaid, Dhari
    SAUDI JOURNAL OF MEDICINE & MEDICAL SCIENCES, 2020, 8 (03): : 241 - 242
  • [45] Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus
    Salukhov, Vladimir V.
    Demidova, Tatiana Y.
    DIABETES MELLITUS, 2016, 19 (06): : 494 - 510
  • [46] ?Not Too Good to be True?: A Proposal to Further Benefit from Emergence in Management Research
    Adrot, Anouck
    MANAGEMENT, 2023, 26 (01): : 85 - 94
  • [47] Benefit of mechanical ventilation during neonatal cardiopulmonary bypass: too good to be true?
    Karl, Tom R.
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2022, 61 (06) : 1289 - 1289
  • [48] Is Relative Mortality of Type 2 Diabetes Mellitus Decreasing?
    Gulliford, Martin C.
    Charlton, Judith
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2009, 169 (04) : 455 - 461
  • [49] Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease
    Fitchett, David
    Inzucchi, Silvio E.
    Lachin, John M.
    Wanner, Christoph
    van de Borne, Philippe
    Mattheus, Michaela
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    George, Jyothis T.
    Zinman, Bernard
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (03) : 364 - 367
  • [50] In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization
    Moist, Louise
    ANNALS OF INTERNAL MEDICINE, 2018, 168 (10) : JC52 - JC52
12345